Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

  1. Nassiri, F.
  2. Patil, V.
  3. Yefet, L.S.
  4. Singh, O.
  5. Liu, J.
  6. Dang, R.M.A.
  7. Yamaguchi, T.N.
  8. Daras, M.
  9. Cloughesy, T.F.
  10. Colman, H.
  11. Kumthekar, P.U.
  12. Chen, C.C.
  13. Aiken, R.
  14. Groves, M.D.
  15. Ong, S.S.
  16. Ramakrishna, R.
  17. Vogelbaum, M.A.
  18. Khagi, S.
  19. Kaley, T.
  20. Melear, J.M.
  21. Peereboom, D.M.
  22. Rodriguez, A.
  23. Yankelevich, M.
  24. Nair, S.G.
  25. Puduvalli, V.K.
  26. Aldape, K.
  27. Gao, A.
  28. López-Janeiro, Á.
  29. de Andrea, C.E.
  30. Alonso, M.M.
  31. Boutros, P.
  32. Robbins, J.
  33. Mason, W.P.
  34. Sonabend, A.M.
  35. Stupp, R.
  36. Fueyo, J.
  37. Gomez-Manzano, C.
  38. Lang, F.F.
  39. Zadeh, G.
  40. Show all authors +
Journal:
Nature Medicine

ISSN: 1546-170X,  1078-8956

Year of publication: 2023

Volume: 29

Issue: 6

Pages: 1370-1378

Type: Article

DOI: 10.1038/S41591-023-02347-Y GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus